Operator: Welcome to the CollPlant Biotechnologies Investor Conference Call to discuss Financial Results for the Second Quarter of 2023 and Corporate Updates.
CollPlant Issues Letter to Shareholders
USA - English
Expansion of collaboration with United Therapeutics to cover a second lifesaving organ, human kidneys, in addition to lungs
Development and commercialization agreement with Allergan Aesthetics, an AbbVie company, for rhCollagen to be used in dermal and soft tissue filler products
Growing revenues and strong cash position, allowing execution of our strategic plan
News provided by
Share this article
Share this article
REHOVOT, Israel, Feb. 18, 2021 /PRNewswire/ CollPlant Biotechnologies (NASDAQ: CLGN) today announced the following letter from its Chief Executive Officer, Yehiel Tal, to its shareholders.
Dear shareholders,
Dermal filler treatment
BioInk development